Machine signal
Active cluster sell — 7 distinct insiders, $29.3M, window ends Sep 17, 2026.
Figures computed from official regulatory filings — .
Analysttarget 140.8 USD (+60%) · consensus 4.94/5 · 16 buy · 0 hold · 0 sell
Ownershipinsiders 0.12% · institutions 127.85% · short 18.1% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for Dianthus Therapeutics, Inc. /DE/ only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
Market information source · Oct 5, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Oct 5, 2026
Open-market timeline · full history
10 buys110 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details | |
|---|---|---|---|---|---|
| CARR EDWARD | Sell | $796.2K | SEC |
| CARR EDWARD | Sell | $73.1K | SEC |
| CARR EDWARD | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| CARR EDWARD | Exercise | $357.6K | SEC |
| CARR EDWARD | Sell | $358.5K | SEC |
| CARR EDWARD | Sell | $113.5K | SEC |
| CARR EDWARD | Sell | $686.4K | SEC |
| Randhawa Simrat | Exercise | $136K | SEC |
| Randhawa Simrat | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Randhawa Simrat | Sell | $766.6K | SEC |
| Randhawa Simrat | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Randhawa Simrat | Sell | $273.5K | SEC |
| Randhawa Simrat | Sell | $1.4M | SEC |
| Randhawa Simrat | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Randhawa Simrat | Exercise | $134.1K | SEC |
| Randhawa Simrat | Exercise | $206.9K | SEC |
| Read Simon | Sell | $326.6K | SEC |
| Read Simon | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Read Simon | Exercise | $51K | Unusual size | SEC |
| Veness Adam M | Exercise | $272.6K | SEC |
| Veness Adam M | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Read Simon | Sell | $7.5K | SEC |
| Read Simon | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Veness Adam M | Exercise | $289.1K | SEC |
| Read Simon | Sell | $52.2K | SEC |